Aurora kinase inhibition as an anticancer strategy

Journal of Clinical Oncology

Volumn 32, Issue 1, 2014, Pages 57-59

  Hilton, John F ^a   Shapiro, Geoffrey I ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALISERTIB; AURORA A KINASE; AURORA B KINASE; AURORA KINASE; AURORA KINASE INHIBITOR; BARASERTIB; CELL CYCLE PROTEIN 20; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DNA; MYC PROTEIN; PACLITAXEL; PROTEIN P21; PROTEIN P53; TOZASERTIB; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; AURORA A KINASE GENE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CELL CYCLE PROGRESSION; CENTROMERE; CHROMOSOMAL INSTABILITY; CHROMOSOME CONDENSATION; CHROMOSOME SEGREGATION; COLORECTAL CANCER; CYTOKINESIS; DNA REPLICATION; ENDOREDUPLICATION; ENZYME INHIBITION; ESOPHAGUS CANCER; G1 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; M PHASE CELL CYCLE CHECKPOINT; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INHIBITION; NONHODGKIN LYMPHOMA; ONCOGENE; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; BURKITT LYMPHOMA; FEMALE; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, T-CELL; MALE; DRUG ANTAGONISM; FOLLICULAR LYMPHOMA; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NOTE; T CELL LYMPHOMA;

ANTINEOPLASTIC AGENTS; AURORA KINASE A; AZEPINES; BURKITT LYMPHOMA; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, T-CELL; MALE; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84894666732     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.7988     Document Type: Article

References (28)

1. Friedberg JW, Mahadevan D, Cebula E, et al: Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol 32:44-50, 2014
2. Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927-936, 2004 (Pubitemid 39626216)
3. Hirota T, Kunitoku N, Sasayama T, et al: Aurora-A and an interacting activator, the LIM protein ajuba, are required for mitotic commitment in human cells. Cell 114:585-598, 2003 (Pubitemid 37159255)
4. Gu J, Gong Y, Huang M, et al: Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 28:350-355, 2007 (Pubitemid 46321850)
5. Sakakura C, Hagiwara A, Yasuoka R, et al: Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 84:824-831, 2001 (Pubitemid 32275658)
6. Dar AA, Goff LW, Majid S, et al: Aurora kinase inhibitors: Rising stars in cancer therapeutics? Mol Cancer Ther 9:268-278, 2010
7. Anand S, Penrhyn-Lowe S, Venkitaraman AR: AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol. Cancer Cell 3:51-62, 2003 (Pubitemid 37443890)
8. Keen N, Taylor S: Mitotic drivers: Inhibitors of the Aurora B kinase. Cancer Metastasis Rev 28:185-195, 2009
9. Terada Y, Tatsuka M, Suzuki F, et al: AIM-1: A mammalian midbody-associated protein required for cytokinesis. EMBO J 17:667-676, 1998 (Pubitemid 28062046)
10. Hauf S, Cole RW, LaTerra S, et al: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 161:281-294, 2003 (Pubitemid 36529847)
11. Ditchfield C, Johnson VL, Tighe A, et al: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 161:267-280, 2003 (Pubitemid 36529846)
12. Smith SL, Bowers NL, Betticher DC, et al: Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br J Cancer 93:719-729, 2005 (Pubitemid 41486464)
13. Holland AJ, Cleveland DW: Beyond genetics: Surprising determinants of cell fate in antitumor drugs. Cancer Cell 14:103-105, 2008
14. Brito DA, Rieder CL: Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr Biol 16:1194-1200, 2006 (Pubitemid 43867292)
15. Gascoigne KE, Taylor SS: Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14:111-122, 2008
16. Tunquist BJ, Woessner RD, Walker DH: Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520. Mol Cancer Ther 9:2046-2056, 2010
17. Huang HC, Shi J, Orth JD, et al: Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16:347-358, 2009
18. Gizatullin F, Yao Y, Kung V, et al: The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function. Cancer Res 66:7668-7677, 2006 (Pubitemid 44289225)
19. Giet R, Petretti C, Prigent C: Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol 15:241-250, 2005 (Pubitemid 40603893)
20. Yang D, Liu H, Goga A, et al: Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Natl Acad Sci U S A 107:13836-13841, 2010
21. Hook KE, Garza SJ, Lira ME, et al: An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 11:710-719, 2012
22. Qi W, Cooke LS, Liu X, et al: Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma. Biochem Pharmacol 81:881-890, 2011
23. Qi W, Spier C, Liu X, et al: Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endoreduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment. Leuk Res 37:434-439, 2013
24. Cervantes A, Elez E, Roda D, et al: Phase I pharmacokinetic/ pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18:4764-4774, 2012
25. Dees EC, Cohen RB, von Mehren M, et al: Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: Safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations. Clin Cancer Res 18:4775-4784, 2012
26. den Hollander J, Rimpi S, Doherty JR, et al: Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 116:1498-1505, 2010
27. Schwartz GK, Carvajal RD, Midgley R, et al: Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. Invest New Drugs 31:370-380, 2013
28. Löwenberg B, Muus P, Ossenkoppele G, et al: Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. Blood 118:6030-6036, 2011